

**Notice of Allowability**

Application No.

10/648,588

Applicant(s)

BOURASSA ET AL.

Examiner

Art Unit

Eisa B Elhilo

1751

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to the application filed on 8/25/2003.2.  The allowed claim(s) is/are 1.3.  The drawings filed on \_\_\_\_\_ are accepted by the Examiner.4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).a)  All    b)  Some\*    c)  None    of the:1.  Certified copies of the priority documents have been received.2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**5.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.6.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.(a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached  
1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.(b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of  
Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

7.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.**Attachment(s)**1.  Notice of References Cited (PTO-892)5.  Notice of Informal Patent Application (PTO-152)2.  Notice of Draftsperson's Patent Drawing Review (PTO-948)6.  Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_.3.  Information Disclosure Statements (PTO-1449 or PTO/SB/08),  
Paper No./Mail Date 8/25/037.  Examiner's Amendment/Comment4.  Examiner's Comment Regarding Requirement for Deposit  
of Biological Material8.  Examiner's Statement of Reasons for Allowance9.  Other \_\_\_\_\_.

Mark Kopec  
Primary Examiner

**DETAILED ACTION**

**EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Martha G. Munchhof on May 17, 2004.

**In the specification:**

**The title:**

Please change the title to read as -- Heterocyclo-alkysulfonyl pyrazole derivatives --.

**The abstract:**

Please change the abstract to read as --The invention relates to compounds of formula 4: Wherein R1- R4 are defined as in the specification--.

2. Claim 1 is allowed.

**STATEMENT OF REASONS FOR ALLOWANCE**

3. The following is an examiner's statement of reasons for allowance:

Cheng et al. (WO 01/40216 A1), teaches and discloses a compound of a formula (I), in which R2 and R3 are hydrogen atoms, R6 is a phenyl group and A is a heterocyclic group of a formula A2, in which X is CH2 radical R5 is hydrogen atom, m is 2 and R4 is an alkyl group (see page 2, formula 1, page 3, formula A2, page 4, lines 29-31 and page 105, formula IA2).

However, the patentee differs from the applicant in that Cheng et al. (WO' 216 A1), does not

Art Unit: 1751

teach or disclose a compound of the claimed formula (1) which comprises a hydroxyl group as claimed. Accordingly, the claimed subject matter as a whole would not have been obvious to one having ordinary skill in the art of chemical formulations.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eisa B Elhilo whose telephone number is (571) 272-1315. The examiner can normally be reached on M - F (8:00 -5:30) with alternate Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yogendra Gupta can be reached on (571) 272-1316. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Eisa Elhilo  
May 17, 2004



Mark Kopec  
Primary Examiner